American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the ...

Dr. Axel Heidenreich presented the final results of the COTRIMS (Cologne trial of retroperitoneal lymphadenectomy in metastatic seminoma) trial. Clinical stage (CS) IIA/B seminoma accounts for only 10 ...

Vaccines for cancer may have seem like a pipe dream a few years ago, but with the great work of scientists and researchers we have made great strides towards cancer treatments. This new vaccine may be ...

A collision on a ski slope led to Liz Healy being diagnosed with two rare cancers. Two months later, she underwent a 10-hour ...

All nine patients showed a “successful anti-cancer immune response” after getting the vaccine. After an average of 34.7 months, they all remained cancer-free.

Initially diagnosed with a tumor on her right kidney, Mazey underwent surgery to remove both the tumor and her kidney before ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

A new personalized cancer vaccine has shown encouraging results in preventing the return of kidney cancer after surgery.